SPDS SET 2: ASH-01

Table-27: Peak area of Withanolide A in sample (B. No. WS/06Lot10) Replicate Conc-1 (753.6 mg/100ml) Conc-2 (1503.2 mg/100ml) Conc-3 (2096.0 mg/100ml) Replicate - 1 382010 797140 1101225

Replicate - 2

393611

784022

1120023

Mean

387810.5

790581

1110624

RSD

1.50

0.83

0.85

Table-28: Peak area of Withanolide B

Withanolide B (mcg/ml)

Different Concentrations

Dilution -6 (21.09)

Dilution -5 (42.19)

Dilution -4 (86.38)

Dilution -3 (172.76)

Dilution -2 (345.51)

Dilution -1 (675.18)

S. solution (1350.36)

553596

1095189

2157826

4196971

7938851

12728719

12264511

Replicate – 1

552800

1094573

2156794

4205282

7947620

12721830

12206630

Replicate – 2

552601

1096209

2156648

4174239

7944196

12736068

12166317

Replicate – 3

552865

1094840

2139922

4205370

7953428

12723957

12126384

Replicate – 4

552430

1093649

2158084

4205743

7963457

12720153

12051739

Replicate – 5

552858

1094892

2153855

4197521

7949510

12726145

12163116

Mean

0.08

0.09

0.36

0.32

0.12

0.05

0.66

RSD

Table-29: Peak area of Withanolide B in sample (B. No. WS/06Lot10) Replicate Conc-1 (753.6 mg/100ml) Conc-2 (1503.2 mg/100ml) Conc-3 (2096.0 mg/100ml) Replicate - 1 122902 242191 336094

Replicate - 2

120722

239205

338649

Mean

121812

240698

337371.5

RSD

0.89

0.62

0.38

4.3.9) Conclusion:

From the above analytical data it is observed that the related standard deviation of peak

areas of different concentrations of Withanoside IV, Withanoside V, Withaferin A, 12-Deoxy withastramonolide, Withanolide A, Withanolide B in sample as well as standard is

<2.0%.

1$785$/ 5(0(',(6

3DJH RI